Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00042952
Status:
TERMINATED
Last Update Posted:
2013-01-17
First Post:
2002-08-05
Brief Title:
Imatinib Mesylate in Treating Patients With Progressive Refractory or Recurrent Stage II or Stage III Testicular or Ovarian Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Testicular Seminoma |
| Ovarian Dysgerminoma |
| Recurrent Malignant Testicular Germ Cell Tumor |
| Recurrent Ovarian Germ Cell Tumor |
| Stage II Malignant Testicular Germ Cell Tumor |
| Stage II Ovarian Germ Cell Tumor |
| Stage III Malignant Testicular Germ Cell Tumor |
| Stage III Ovarian Germ Cell Tumor |
Keywords: